期刊文献+

不同浓度肝素钠疏通深静脉导管完全堵塞的疗效观察 被引量:1

The efficacy of different concentrations of heparin to clear deep venous catheter completely blocked
下载PDF
导出
摘要 目的探讨应用不同浓度的肝素钠疏通患者深静脉导管完全堵塞的疗效。方法对近3年来化疗患者深静脉导管完全堵塞分别采用浓度为30U/ml、60U/ml、90U/ml和120U/ml肝素钠溶液进行溶解疏通,并记录导管再通率、再通时间和并发症情况。结果 30U/ml、60U/ml、90U/ml和120U/ml 4种肝素钠溶液再通率分别为57.5%、72.5%、87.5%和92.5%,总再通率为77.5%,4种浓度再通率差异有统计学意义(P<0.05);4种浓度的平均再通时间差异无统计学意义(P>0.05);未发生与使用肝素钠有关的并发症。结论对化疗患者堵塞的深静脉导管及时应用肝素钠溶液可安全有效地恢复导管的通畅。 Objective To investigate the efficacy of different concentrations of heparin to clear deep venous catheter com- pletely blocked. Methods Chemotherapy in patients, with deep venous catheter completely blocked in the past three years in our hospital, were treated with different concentrations of 30U/ml 60u/ml, 90U/mL, and 120U/mL heparin solution dissolved to dredge and recorded the catheter recanalization rate, time and concurrency recanalization diseases. Results The heparin solution recanalization rate of 30U/ml 60u/ml 90U/ml and 120U/ml respectively was 57.5% , 72.5% , 87.5% and 92.5% , total reca- nalization rate was 77.5%, the differences of four concentrations of recanalization rate were statistically significant ( P 〈 0.05 ), the differences of four concentrations of the average recanalization time were not statistically significant( P 〉 0. 05 ), and it did not occur with the sodium heparin-related complications. Conclusion Chemotherapy in patients with deep venous catheter blockage, timely application of heparin solution could be safe and effective in restoring patency of the catheter.
作者 陈飞燕
出处 《四川医学》 CAS 2013年第9期1409-1411,共3页 Sichuan Medical Journal
关键词 肝素钠 深静脉导管 导管堵塞 heparin deep venous catheter catheter blockage
  • 相关文献

参考文献9

  • 1牛玉玲.糖尿病患者应用套管针肝素液封管浓度的研究[J].中国实用护理杂志,2008,24(9):23-24. 被引量:5
  • 2Beathard GA. Catheter thrombosis[J].{H}Seminars in Dialysis,2001.441-445.
  • 3Svoboda P,Barton RP,Barbarash OL. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices:a multiplecenter,international trial[J].{H}CRITICAL CARE MEDICINE,2004.1990-1996.
  • 4Horne MK. Thrombolytics for occluded catheters[J].{H}CRITICAL CARE MEDICINE,2004.2146-2147.
  • 5McMahon GS,CI Jones,PD Hayes. Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenase.Findings from a randomised controlled trial[J].{H}Thrombosis and Haemostasis,2013,(05):125-128.
  • 6Wu MY,YH Hsu,CH Bai. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy:a meta-analysis of randomized controlled trials[J].{H}American Journal of Kidney Disease,2012,(06):810-818.
  • 7Chen FF,WH Lin,SC Lin. Significance of heparin binding to basic residues in homologous to the amino terminus of hepatoma-derived growth factor and related proteins[J].{H}GLYCOBIOLOGY,2012,(05):649-661.
  • 8Mousa SA. Comparative pharmacodynamic assessment of the antiangiogenesis activity of heparin and low-molecular-weight heparin fractions:structure-function relationship[J].{H}Clin Appl Thrombosis/Hemostasis,2013,(01):48-54.
  • 9Brown RA,E Leung,H Kankaanranta. Effects of heparin and related drugs on neutrophil function[J].{H}PULMONARY PHARMACOLOGY & THERAPEUTICS,2012,(02):185-192.

二级参考文献5

共引文献4

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部